

Index

A

- A to Z Guide: Sex and Gender Influences on Health, 14
- abdominal aortic aneurysm, 95
- abdominal fat, 145–146
- acetaminophen, 252
- ACRWH. *See* Advisory Committee on Research on Women's Health
- ADHD, 261
- Administrative Supplements for Research on Sex/Gender Differences program, 8, 9–10, 106, 121, 140, 213, 216, 247, 255, 293
- adolescent idiopathic scoliosis, 147
- adolescents
- alcohol use and, 117, 121
 - asthma in, 135
 - cannabis use, 225
 - cerebral perfusion and, 260
 - contraception for, 170
 - diabetes in, 204
 - drug use/abuse in, 229
 - HIV/AIDS and, 274, 294
 - Internet obesity prevention programs, 292
 - pregnancy in, 170, 271–272, 292
 - risk-taking, 229–230
 - sexual activity, risk reduction, 294–295
 - sexual behavior, high-risk, 229–230
 - stress in, 320–321
- Advancing Novel Science in Women's Health Research Program (ANSWHR), 11, 155–156, 199
- Advisory Committee on Research on Women's Health (ACRWH), viii, 1
- Africa, human health and heredity in, 329
- See also specific countries*
- African-American women
- AIDS in, 294
 - criminal justice and health disparities, 270
 - diabetes and heart disease risk, 204
 - fibroids in, 250
 - HIV/STI intervention for drug-involved, 233
 - obesity in, 202, 291
 - obesity prevention in girls, 272
 - preeclampsia in, 290
 - preterm birth in, 273
 - spirituality, and coping with type 2 diabetes, 294
 - stroke literacy and intent to call 9-1-1, 285
- African Organization for Research and Training in Cancer (AORTIC), 81
- Age-Related Eye Disease Study (AREDS), 91
- age-related macular degeneration, 91
- Agency for Healthcare Research and Quality (AHRQ), 19
- aging, 106–115, 289–290, 318–319
- balance confidence and, 290
 - cognition and, 106, 107, 109–111, 112–113
 - fragility fractures and, 144
 - mental health and, 261–262
 - NIH research budget for, 61
 - reproductive, 1–6
 - sex and gender differences, 113–114
- Agricultural Health Study (AHS), 244
- AIDS, 123–124, 267, 294
- AIDS Clinical Trials Group (ACTG), 129, 139
 - Centers for AIDS Research (CFAR), 130
 - nevirapine-resistant mutations, 72
 - See also* HIV/AIDS
- AIDS International Training and Research Program (AITRP), 300, 302–303
- air pollution
- household, 245, 249, 303
 - prenatal exposure to, 242
- alcohol, 116–122
- adolescents and, 117, 121
 - binge drinking, 315

- cancer and, 120
 - college drinkers, 118
 - effects on IBS, 289
 - fetal alcohol spectrum disorders (FASD), 118
 - pregnancy and, 118, 121, 315
 - sex/gender differences, 116–118, 121
 - stress and, 117
 - violence and, 118
 - young women, use in, 119–120
 - alcohol abuse, 116–122
 - prevention and treatment, 119–120
 - alcoholism, 116–122
 - twin study, 120
 - allergies, 122–143
 - Alzheimer’s disease, 106, 111, 175, 179
 - menopausal hormone therapy and, 109–110
 - monkey model of, 318–319
 - perimenopause and, 113
 - tamoxifen and, 110–111
 - animal models, 4, 7, 310, 324–325
 - Anita B. Roberts Lecture Series, 32
 - ANSWHR (Advancing Novel Science in Women’s Health Research), 11, 155–156, 199
 - antagonistic co-evolution of males and females, 254
 - anterior cruciate ligament injuries, 147–148
 - antibiotics
 - during pregnancy, 171–172, 317
 - in early life, 206–207
 - for UTIs, 212
 - antidepressants, 262, 263
 - antiepileptic drugs, 278, 280, 282
 - antioxidants, 170
 - antiretroviral therapy (ARV), 122, 123, 129–130
 - atazanavir, ritonavir, efavirenz, lamivudine, and tenofovir, 129–130
 - dapivirine, 126
 - genital ulcers and, 133–134
 - maraviroc, 126
 - anxiety
 - alcohol use in females and, 116–117
 - perimenopausal, 108, 262
 - AREDS (Age-Related Eye Disease Study), 91
 - Army STARRS, 266
 - arthritis, 144–158
 - osteoarthritis, 147–148, 154, 155, 175
 - rheumatoid arthritis, 144, 148–150
 - ASPIRE Trial, 126
 - aspirin, 70, 79, 279
 - asthma, 97, 104, 135–136, 247
 - infant and childhood, 135–136
 - atherosclerosis, 281
 - attention-deficit hyperactivity disorder (ADHD), 261
 - autoimmune diseases, 136–138, 154, 155, 195–197
 - environmental exposures and, 247
 - autoimmunity, 138
- B**
- B-cell activation factor (BAFF), 196
 - balance confidence, 290
 - balance disorders, 185–186
 - bariatric surgery, 205–206, 215–216, 217
 - basal forebrain cholinergic neuron (BFCN) system, 175
 - behavior, 106, 319–321
 - behavioral health, 261
 - behavioral studies, budget for, 62
 - bevacizumab, 77–78
 - biliary pain, 210
 - Bill & Melinda Gates Foundation, 57
 - binge drinking, 315
 - bioengineering, 158–166
 - See *also* imaging technologies
 - biomaterial-based breast cancer vaccine, 162
 - biomedical careers, women in, 19–35
 - See *also* career development; ORWH biomedical career development activities
 - BIRCWH program, 8, 19–25, 156, 176, 246
 - annual meetings, 25
 - current awardees, 20–21

- directory of scholars, 25
- K12 program, 19
- ORWH support for, 19–20, 34
- outcomes to date, 22–23
- research highlights and topics, 23–25
- statistics on awardees, 22–23
- Web site, 25
- birth. *See* childbirth
- birth cohorts, 216
- birth defects, 121–122, 179
- bisphenol A (BPA), 242, 244, 317
- bisphosphonates, 192–193
- Black women. *See* African-American women
- bladder disorders/health, 12–13, 217
- blood disorders, 98
- blood pressure, 166, 292
- blood vessels, 16–17, 282
- body fat, 312
- bone biology, 144, 146, 191–193
- bone cells, 146, 192
- bone diseases, 64
- bone formation, 146, 192
- bone health, 108, 113, 146, 154, 192
- bone mass, 192
- bone mineral density (BMD), 144, 146, 173, 192, 289, 308–309
- bone quality, 155
- bone strength, 144, 145–146
- botanical supplements, 308, 309
- Bowel Control Awareness Campaign, 214
- BPA. *See* bisphenol A
- brachytherapy, 162
- brachyury, 73
- Brady, Kathleen, 222
- brain, 300
 - basal forebrain cholinergic neuron system, 175
 - BRAIN Initiative, 12, 283
 - Brain program, 303, 305
 - gut microbiota and, 267
 - hormones and, 146
 - innovative neurotechnologies (BRAIN Initiative), 12, 283
 - newborn brain injury, 174–175
 - prefrontal cortex, 259, 260
 - sex differences in, 175, 257–260
- brain cancer, 72
- BRAIN Initiative, 12, 283
- Brain program, 303, 305
- BRCA genes, 70, 78, 79, 209
- breast cancer, 70, 72–75, 159–162
 - alcohol and, 120
 - biomaterial-based vaccine, 162
 - brachyury and, 73
 - BRCA genes, 70, 78, 79, 209
 - CD44 as prognostic marker, 73
 - CYP2D6 genotype in, 253–254
 - digital breast tomosynthesis (DBT), 159
 - double mastectomy vs. lumpectomy, 74
 - entinostat and, 74
 - environment and, 243, 247–248
 - EZH2 and triple-negative breast cancers, 73
 - GATA3 transcription factor, 72–73
 - health disparities in, 85–86, 288
 - imaging and treatment, 159–162
 - Latinas/Hispanics and, 85–86
 - literacy, 288
 - minorities and, 85
 - mortality rates, 70, 71
 - NIH research budget for, 60
 - NOS2 and, 73
 - obesity and, 75, 86
 - PALB2 gene, 70, 72
 - premenopausal, estrogens and, 75
 - prevention, 74–75, 243
 - risk factors, 75
 - screening, 73–74
 - Sister Study, 245
 - sun exposure and, 244
 - triple-negative (TNBC), 73
 - tumor margins, rapid imaging of, 161–162

- unemployment after chemotherapy, 74
- yoga and, 74
- breast cancer treatment, 74, 208–209
 - chemotherapy, cognition and, 110–111
 - chemotherapy, unemployment after, 74
 - drug delivery systems, 159, 160, 161
 - NEET proteins, 252
 - PARP1 inhibitor, 209
 - radiofrequency ablation, with robotic haptic feedback, 161
 - sponge compound and, 254–255
 - symptom clusters and, 288
 - tamoxifen, 110–111, 253–254
 - thermally targeted drug delivery, 160
- breast milk, 127, 291
- breastfeeding, 179, 290
- brown fat, 192
- budget (NIH, for women’s health research), 59–67
 - calculation of, 59–60
 - by disease, condition, and special initiatives, 60–66
 - by sex, 67
- Building Interdisciplinary Research Careers in Women’s Health. *See* BIRCWH
- bupropion, 231
- Burkitt lymphoma, 75
- burning mouth syndrome (BMS), 188
- bupirone, 231

C

- C. elegans*, 254
- C-reactive protein (CRP), 293
- cancer, 70–88
 - alcohol use and, 120
 - fertility preservation for female patients, 164–165
 - genes and, 70
 - global cancer research, centers, and programs, 83–84
 - incidence rates, 70–71, 72
 - low-cost technologies for low- and middle-income countries, 83
 - mortality rates, 70–71
 - Native Americans and, 274
 - NIH research budget for, 60
 - See also specific types of cancer*
- cannabis, 225, 232–233
- capacity building, 267, 300, 302
- carboplatin, 79
- cardiac annunciator, 164
- cardiology, BIRCWH research in, 24
- cardiovascular disease (CVD), 93, 94–97, 99–102
 - cognitive decline and, 110
 - lifestyle interventions, 205
 - lupus and, 150
 - menopausal predictors of, 96
 - NIH research budget for, 61
 - pregnancy and, 102
 - risk, race/ethnicity and, 204
 - risk, sex differences in, 207
 - SWAN study, 108
 - triglyceride tests, 204
- cardiovascular research, sex bias in, 102
- career development, 19–35, 295–296
 - Anita B. Roberts Lecture Series, 32
 - BIRCWH program, 19–25, 156, 176
 - Committee on Research and Evidence to Promote Women in Scientific Careers, 30
 - Committee on Women of Color in Biomedical Careers (WOC), 29–30
 - continuing education, 33
 - Eunice Kennedy Shriver* National Institute of Child Health and Human Development, 176
 - Fogarty International Center Global Health Program for Fellows and Scholars, 32
 - Foundation for Advanced Education in the Sciences High School Summer Student Program, 33
 - Intramural Program on Research on Women’s Health (IPRWH), 31
 - National Institute of Diabetes and Digestive and Kidney Diseases Travel Awards, 32

- National Institute of Nursing Research, 295–297
- National Institute on Aging, 114–115
- NIH Women in Science Web site, 29
- NIH Working Group on Women in Biomedical Careers, 28–31, 34
- Office of Intramural Training and Education (OITE), 32
- Office of Research Infrastructure Programs (ORIP) programs, 321–322
- online courses: Science of Sex and Gender in Human Health, 33, 34
- ORWH career development activities, 19–35
- ORWH support of NIH Strategic Plan for Women’s Health Research, 34
- Reentry into Biomedical Research Careers, 28, 34, 283
- for veterinarians, in laboratory animal medicine, 321–322
- Women of Color Research Network (WoCRn), 29, 34, 115
- Women’s Reproductive Health Research (WRHR) program, 26–27, 34
- Working Group initiatives for NIH employees, 30–31
- workplace culture, impact of, 283
- Carroll, Marilyn, 223
- cataracts, 90–91
- CBT. *See* cognitive behavior therapy
- CD4+ T cells, 313
- cediranib, 79
- cell-cell communication systems, surrogates for, 162–163
- cell phone-based protocols, 164
- Cellular Signatures, Library of (LINCS), 330
- Center for Point-of-Care (POC) Tests for Sexually Transmitted Diseases, 162
- Centers for AIDS Research (CFAR), 130
- cerebrovascular events/disease. *See* stroke
- Cerenkov imaging, 161
- cervical cancer, 70–71, 75–78, 83
 - bevacizumab with chemotherapy, 77–78
 - biopsies, multiple vs. single, 76–77
 - HPV types and, 76
 - HPV vaccines, 77
 - national meeting in Costa Rica, 84–85
 - Pap tests in older women, 76
 - prevention, 77, 85
 - screening, 75–77, 82, 85
 - treatment, 77–78
- cervical cerclage, 173
- cervical mucus, 163
- cesarean delivery, 172
- CFS. *See* chronic fatigue syndrome
- chaetoglobosin, 253
- Chagas disease, 132
- CHD. *See* coronary heart disease
- chemotherapy
 - for breast cancer, 74, 110–111
 - cognition and, 110–111
 - during pregnancy, 242–243
 - nanoparticle delivery, 74, 160
 - tamoxifen, 110–111, 253–254
 - unemployment after, 74
- child care, 30, 31
- child health
 - oral health, 194
 - urinary tract infections and, 212
- child sexual abuse, 108
- childbirth, 290–291
 - birth defects, 121–122, 179
 - chronic pain following, 252–253
 - low birthweight, 174, 291
 - preterm, 173, 263, 273, 317
 - stillbirths, 164, 178
- childhood abuse, 229
- childhood pneumonia, cell phone-based protocols, 164
- children, environmental health and disease, 247
- chorioamnionitis, 317
- chronic conditions, 288–289
- chronic fatigue syndrome (CFS), 122, 199, 281
- Chronic, Non-Communicable Diseases and Disorders Across the Lifespan, 299, 301, 305

chronic pain, 16, 151–152, 188, 277–278
 chronic overlapping pain conditions, 188, 199, 284
 chronic pelvic pain, 12–13, 211, 215
 following childbirth, 252–253
 migraines, 279–280
 sleep disturbances and, 16
 cisplatin, 253
 claudins, 113
 Clayton, Janine, v, 4, 7
 cleft lip/palate, 198
 clinical research
 coding categories, 41
 definition of, 40
 enrolling pregnant women in, 56–57
 inclusion of women and minorities as subjects, 4–5, 37–57
 monitoring adherence to NIH inclusion policy, 37–57
 peer review, 38
 Summary Report of NIH Inclusion Data, 40–55
 See also inclusion of women and minorities; phase III clinical trials
 Clinical Research, Inclusion, and You (seminar), 55–56
 Clinical Trials Network (CTN), 235
 cocaine, 223, 226, 231
 prenatal, 228–229
 cofunded research initiatives, 8, 12–14
 cognition, 106, 260, 261
 aging and, 106, 107, 109–111, 112–113
 breast cancer chemotherapy and, 110–111
 cognitive aging, 106, 112–113
 hormone therapy and, 109–110, 112–113
 hypogonadism and, 259
 KEEPS-Cog study, 106, 110
 menopause and, 261–262, 309
 tamoxifen and, 110–111
 cognitive aging, 106, 112–113
 cognitive behavior therapy (CBT), 151
 cognitive decline, 110–111, 303
 cognitive disorders and dementia, 303
 cognitive health, 106, 109–110
 Collins, Francis, 7, 222
 colorectal cancer, 60, 70, 71
 Committee on Research and Evidence to Promote Women in Scientific Careers, 30
 Committee on Women of Color in Biomedical Careers (WOC), 29–30
 communication disorders, 183–187
 complementary and integrative health, 307–310
 conferences and workshops, 14–17
 See also specific Institutes
 congenital adrenal hyperplasia (CAH), 169
 Congressional Caucus for Women’s Issues, 1
 contraception, 167, 170, 178, 314–316
 female contraceptive development, 177
 nonhormonal contraceptive, 315–316
 nonsurgical permanent contraception, 315
 oral contraceptives, 174, 224
 ovary-based contraceptives, 315
 polidocanol foam (PF), 315
 Sperm Acrosomal SLLP1 Binding (SAS1B), 316
 Contraceptive Choice Project, 170
 cookstoves, 245, 303, 304
 Coordinating Committee on Research on Women’s Health (CCRWH), 1, 7, 59
 corneal endothelial dystrophy, 89
 coronary artery disease (CAD), 101
 coronary heart disease (CHD), 95, 101, 103
 craniofacial anomalies, 197–198
 craniosynostosis, 198
 criminal history, effects on women’s health, 271
 criminal justice system
 African-American women and, 270
 health disparities and, 270
 interventions for women and girls in, 230
 re-entry needs of women, 261
 teens in, HIV/AIDS and, 274
 Crohn’s disease, 137
 cryopreservation, 316

CVD. *See* cardiovascular disease

CYP2D6 genotype, 253–254

cystic fibrosis, 98

cytomegalovirus (CMV), 184

D

dapivirine, 126

deafness, 183–187

Deepwater Horizon Gulf Oil Spill (2010), 249

depression, 258, 262

aging and, 107, 108

antidepressants, 262, 263

cognitive decline and, 111

intensive lifestyle intervention and, 205

major depressive disorder (MDD), 108

maternity leave benefits and, 111

perimenopausal, 108

postpartum, 172, 258

recurrence, menopause and, 262

STOP-PD (psychotic depression) trial, 266

treatment, 262, 263

diabetes, 202, 203–205, 218

bone strength in, 145

care, 216

gestational, 178, 202, 204–205, 208, 271

intensive lifestyle intervention, 203–204, 205

Korean immigrants with, 294

Look AHEAD trial, 205

metformin for, 203

mobile app in Spanish/English, 271

obesity and, 312

pesticides and, 244

prevention, 203–204, 216

risk of, 203–204

sex and gender differences in, 13

spirituality in coping with, 294

TODAY study, 204, 215

type 2, 203–204, 294

in youth, 204

Diabetes Prevention Program (DPP), 13, 203–204, 217–218

Diabetes Prevention Program Outcomes Study (DPPOS), 13, 203, 215, 217–218

diet, 292, 319

dietary supplements, 20, 307–308, 309

digestive conditions and diseases, 202, 209–210, 220

digital breast tomosynthesis (DBT), 159

disinhibition, 226–227

disorders or differences of sex development (DSD), 169, 179

dissemination activities, 14–17

Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), 1

DNA methylation, 241, 242, 278

Down syndrome, 175, 179

DPP (Diabetes Prevention Program), 13, 203–204, 217–218

DPP Outcomes Study (DPPOS), 13, 203, 215, 217–218

DREAM program (NIMHD), 274

drinking. *See alcohol entries*

drug abuse, 221–239

disinhibition in, 226–227

health disparities and, 232–233

treatment, gender issues in, 225–227

drug addictions

genetic variants and, 231–232

HIV/STI intervention, 233

treatment medications for, 230–232

drug delivery systems, 74, 150, 159, 161

thermally targeted, 160

drug use in pregnancy, 172, 227, 228–229

dry-eye, 89–90

dry mouth, 195

dura mater, 279–280

dynorphin, 228

E

eating disorders, 266

elastin-like polypeptide nanoparticles (ELPs), 160

ELITE trial, 113

embryo quality, 179

emergency care, 284

emotional feeding, 319

emotions, 261

endocrine disease, imaging of, 163

endocrine disruptors, 242, 244, 248

endocrinology, 24, 62, 208–209, 219

endoglin, 290

endometrial cancer, 78

endometriosis, 170

endoxifen, 253–254

entinostat, 74

environment, 240–251

- Deepwater Horizon Gulf Oil Spill, 249
- factors in reproductive disorders, 254
- health effects of, 65
- toxins, prenatal or perinatal exposure, 318

epigenetic determinants, 273

epilepsy, 277, 278, 280

Escherichia coli, uropathogenic (UPEC), 211

ESTAMPA, 82

estradiol, 189, 280, 316

estrogen receptors (ER), 146

estrogen replacement. *See* hormone therapy

estrogenic effects of off-the-shelf hair and skin care products, 243

estrogens, 259, 316

- botanical, 309
- breast cancer risk, 75
- environmental, 65
- gene expression in uterus and, 242
- measuring exposure and metabolism, 85
- neuroprotection from MS, 281

See also menopausal hormone therapy

ethnicity. *See* race/ethnicity

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), 19, 26, 39, 57, 167–182

BIRCWH awardees, 20–21

branches of, 167–168

career development for women in science, 176

Contraceptive Discovery and Development Branch (CDDB), 167

Fertility and Infertility (FI) Branch, 167

funding initiatives, workshops, and conferences, 177–180

Gynecological Health and Disease Branch (GHDB), 167

health disparities, 180–181

Health Equity Seminar Series, 180

inclusion, 176–177

Maternal and Pediatric Infectious Disease Branch (MPIDB), 167–168

NIH Strategic Plan, 168–169

Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB), 168

Pregnancy and Perinatology Branch (PPB), 168

research accomplishments in women's health, 170–174

research advances in sex and gender influences on health and disease, 174–176

Subcommittee on Inclusion Governance and, 39

exercise, benefits of, 108

extracellular matrix, 162–163

eye disorders, 64, 89–93

F

Family Check-Up (FCU) intervention, 229–230

family planning, 302

fatigue. *See* chronic fatigue syndrome

fecal incontinence, 217, 220

fertility, 167, 314–316

- binge drinking and, 315
- contraception and, 315–316
- cryopreservation, 316
- infertility and, 164–165, 167, 170, 178

- preservation in cancer patients, 164–165
- fetal alcohol spectrum disorders (FASD), 118
- fetal cells, role in stroke recovery, 280
- fetal MRI, 163
- fetal neurological assessment, 164
- fetal ventriculomegaly, 163
- fetus, maternal undernutrition and, 318
- fibroids, 173, 180, 250
- fibromyalgia, 151–152
- FOAs (funding opportunity announcements), 7–8
- focal dermal hypoplasia (FDH), 312
- Fogarty International Center, 32, 299–307
 - accomplishments and activities, 245, 300–304
 - AIDS International Training and Research Program (AITRP), 300, 302–303
 - Brain program, 303, 305
 - Chronic, Non-Communicable Diseases and Disorders Across the Lifespan, 299, 301, 305
 - funding initiatives, workshops, and conferences, 305–306
 - Global Brain and Nervous System Disorders Research Across the Lifespan, 300, 303
 - Global Health Program for Fellows and Scholars, 299, 301–302, 305
 - health disparities, 306
 - HIV Research Training Program, 303, 305
 - household air pollution, 303
 - inclusion, 305
 - International Research Scientist Development Award, 299, 300–301
 - International Tobacco and Health Research and Capacity Building Program, 300, 302
 - Medical Education Partnership Initiative (MEPI), 304
 - Mobile Health (mHealth) program, 299, 301
 - NIH Strategic Plan, 304
 - preventing mother-to-child transmission of HIV (PMTCT), 300, 303–304, 306
 - STEM efforts, 305
 - Trauma and Injury Research Training Program, 299, 300, 306

- Fonds de Recherche du Québec (FRQ), 31
- Food and Drug Administration (FDA), 9, 33, 76, 90
- foodborne pathogens, 132
- fractures/fracture risk, 145–146, 289
- Fragile Families Study, 271
- fragile X, 179, 207
- Framingham Heart Study, 100
- free fatty acid (FFA) flux, 175
- funding opportunity announcements (FOAs), 7–8
- Fusion Inhibitor, 313–314

G

- gallbladder, 210
- gamete quality, 179
- gastric bypass surgery, 205–206
- gender
 - antagonistic co-evolution of males and females, 254
 - inclusion of both sexes in clinical research, 4–5, 10, 37–57
 - See *also* sex; sex and gender factors; sex/gender differences
- genetics, BIRCWH research topics, 24
- genistein, 308, 309
- genital herpes, 134, 295
- genital ulcers, 133–134
- genotype-tissue expression (GTEx), 329
- gestational diabetes, 178, 202, 204–205, 208
 - mobile app in Spanish for women with prior, 271
- Ghana, 301
- glaucoma, 91–92
- Global Brain and Nervous System Disorders Research Across the Lifespan, 300
- Global Grand Challenges (NIMH), 264
- Global Health Program for Fellows and Scholars, 299, 301–302, 305
- Global Health program (NIH Common Fund), 329
- Global Research Hubs (NIMH), 264
- GlobalTracks* newsletter, 266

gonadotropin-releasing hormone (GnRH), 314–315
Graves' disease. *See* thyroid eye disease
guanfacine, 223, 231
gut microbes, 149, 267, 309
gynecologic health, 167
gynecology, BIRCWH research topics, 24

H

H3Africa, 329
HAPO study, 208
headache. *See* migraines
health disparities, 269–276

- in cancer, 85–86, 288
- cardiovascular and heart disease, 103–104
- in criminal justice system, 270
- Deepwater Horizon Gulf Spill and, 249
- Eunice Kennedy Shriver* National Institute of Child Health and Human Development, 180–181
- Fogarty International Center, 306
- Get in the GROOVE!, 323
- Health Equity Seminar Series (NICHD), 180
- in Korean immigrants with diabetes, 294
- National Cancer Institute, 85–86
- National Heart, Lung, and Blood Institute, 103–104
- National Institute of Allergy and Infectious Diseases, 140–141
- National Institute of Biomedical Imaging and Bioengineering, 166
- National Institute of Dental and Craniofacial Research, 193–194, 200
- National Institute of Diabetes and Digestive and Kidney Diseases, 217–218
- National Institute of Environmental Health Sciences, 249
- National Institute of Mental Health, 257, 267–268
- National Institute of Nursing Research, 293, 294
- National Institute on Aging, 114
- National Institute on Drug Abuse, 232–233
- National Institute on Minority Health and Health Disparities, 274, 276

Native Americans, 274
Office for Research on Disparities and Global Mental Health, 257, 263
Office of Research Infrastructure Programs, 323
oral health, 193–194, 273
hearing, 186
heart disease, 93
heart transplantation, 293
The Heart Truth, 99–100
hepatic glutathione (GSH), 252
hepatitis E virus (HEV), 134
heroin, 226
herpes simplex virus, 133–134, 315
High Risk, High Reward program, 329–330
high school summer student program, 33
hip fractures, 145
Hispanic Community Health Study, 100, 103
Hispanic women, 270–271, 292

- AIDS in, 294
- breast cancer and, 85–86
- mobile app for diabetes in Spanish, 271
- Project SAFE in Spanish (C-SEGURA), 270–271

HIV (human immunodeficiency virus), 123–130

- cognition and, 261
- estimating incidence of, 128
- family planning and, 302
- life expectancies, 124–125, 129
- menstrual cycle phase and, 314
- mother-to-child transmission, prevention of, 127–128, 177–178, 300, 303–304, 306
- natural history of, 124
- oral health and, 197
- osteoporosis and, 130
- President's Emergency Plan for AIDS Relief (PEPFAR), 300
- prevention, 125–129, 140, 267, 274
- prevention, intimate partner violence and, 259
- Research Training Program (Fogarty Center), 303, 305
- risk factors for women in the U.S., 128–129

- risk perception in college women, 295
 - superinfection, 124
 - treatment in criminal justice settings, 230
 - vaccines and vaccination, 128, 273, 313
 - vaginal transmission, preventing, 313, 314
 - Women's Interagency HIV Study (WIHS), 123, 124, 139
 - HIV/AIDS, 123–130, 294–295, 312–314
 - adolescent girls and, 274, 294
 - antiretroviral therapy (ARV), 122, 123, 129–130, 133–134
 - ASPIRE Trial, 126
 - control of virus replication, 312–313
 - epidemiologic research, 124–125
 - Fusion Inhibitor and, 313–314
 - genetic loci, 312–313
 - genital ulcers and, 133–134
 - leDEA, 125, 139
 - intravaginal ring (IVR), 126
 - Native Americans and, 267
 - prevention, 125–129, 140, 274, 313–314
 - risk of neonatal vaccination, 313
 - therapeutics research, 129–130
 - topical microbicides, 125–127, 139
 - UNAIDS, 123
 - vitamin D and, 130
 - VOICE trials, 125–126
 - homeless women, 119
 - hormone therapy
 - bone density and, 173
 - menopausal, 109–110, 112–113, 262
 - risks of, 100
 - See also* sex hormones
 - hot flashes, 289, 309
 - nonhormonal treatment for (MsFLASH), 109, 112, 114
 - household air pollution, 245, 249, 303
 - HPV (human papillomavirus), 70, 71, 76, 81–82, 133
 - cancers associated with, 70, 71, 76
 - cervical cancer and, 76
 - oral infection, 195
 - oropharyngeal cancer and, 78, 81
 - tests for, 75, 76, 84, 85
 - HPV vaccines, 70, 77, 78, 82
 - human development. *See Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)*
 - human immunodeficiency virus. *See* HIV
 - human papillomavirus. *See* HPV
 - Human Placenta Project, 168, 180
 - hypertension
 - idiopathic intracranial hypertension (IIH), 92
 - pregnancy-related, 110
 - hypogonadism, 259
- I**
- IBS. *See* irritable bowel syndrome
 - idiopathic intracranial hypertension (IIH), 92
 - leDEA (International Epidemiologic Databases to Evaluate AIDS), 125, 139
 - imaging technologies, 158–166
 - breast cancer, 159–162
 - Cerenkov-specific contrast agents, 161
 - digital breast tomosynthesis (DBT), 159
 - digital specimen tomosynthesis, 161
 - early disease detection and, 159
 - magnetic resonance elastography, 160
 - MRI, 159–160, 161
 - near-infrared light imaging with ultrasound guidance, 160–161
 - neuroimaging, 260
 - proton-electron double-resonance imaging, 161
 - rapid imaging of breast tumor margins, 161–162
 - robotic haptic feedback, 161
 - steroid-based contrast agents for MRI, 163
 - for temporomandibular joint, 190–191
 - ultrasound, 160–161, 163–164
 - volumetric imaging, 161
 - whole-breast MRI at 3.0T, 159–160
 - immune disorders, NIH research budget for, 63

immune function, 319–320
 immune-mediated diseases, 135–138
 immunization. *See* vaccines
 immunology, 135–138, 267
 IMPAACT trial, 127
 inclusion of women and minorities as subjects in
 clinical research, 4–5, 10, 37–57
 adherence to NIH policy on, 37–57
 business processes and procedures, 39
 Clinical Research, Inclusion, and You (seminar),
 55–56
 communication and outreach concerning, 38, 55
 data for monitoring, 37, 39
 historical perspective, 37
 inclusion enrollment data, 38, 40–55
 inclusion monitoring activities of NIH, 38
 inclusion of pregnant women, 56–57
 Inclusion Policy Officer (NIH), 39
 interpreting NIH inclusion data, 40–41
 key trends, summary, 41
 monitoring adherence to NIH policy on, 37–57
 NIH coding categories, 41
 NIH efforts to re-engineer, 39
 NIH funding life cycle, 40
 NIH policy on, 37
 NIH Revitalization Act, 37
 NIH Task Force on, 39
 NIH Workshop on Enrollment and Retention of
 Participants in Clinical Trials, 55
 ORWH activities related to, 55–57
 peer review and, 38
 phase III clinical trials, 37, 38, 39, 45–47, 53–54
 population data analysis, 38
 staff training in inclusion policy, 83
 Summary Report of NIH Inclusion Data, 40–55
 *Women’s Health: NIH Increased Efforts to
 Include Women in Research* (report, 2000), 37
 See also specific Institutes and Centers
 inclusion of women and minorities: data on, 40–55
 acceptability of inclusion plans, 42
 coding categories, 41
 enrollment of minorities in clinical research, 41,
 48–50, 53–54
 enrollment of minorities in phase III clinical trials,
 41, 50–54
 enrollment of women in clinical research, 41, 44,
 53–54
 enrollment of women in phase III clinical trials,
 41, 45–47, 53–54
 interpretation of inclusion data, 40–41
 NIH funding life cycle and, 40
 portfolio composition, 40
 race/ethnicity: aggregate enrollment, 48–54
 race/ethnicity: enrollment in clinical research,
 48–50, 53–54
 race/ethnicity: enrollment in phase III clinical
 trials, 50–54
 sex/gender: aggregate enrollment, 43–47, 53–54
 sex/gender: trends in clinical research, 43–45,
 53–54
 sex/gender: trends in phase III clinical trials,
 45–47, 53–54
 summary of trends, 41, 55
 incontinence
 fecal, 217, 220
 urinary, 12, 289–290
 India, intimate partner violence in, 301
 infectious diseases, 122–143
 BIRCWH research topics, 24
 maternal and pediatric, 167–168
 NIH research budget for, 63
 infertility, 164–165, 167, 170, 178, 315
 mitochondrial replacement therapy and, 315
 See also fertility
 inflammation, 155, 272
 influenza, 132–133
 during pregnancy, 172
 vaccination during pregnancy, 133, 240
 infrastructure. *See* Office of Research Infrastructure
 Programs
 Institutes and Centers, NIH, 69–330
 insulin-like growth factor-I, 72

intensive lifestyle intervention (ILI), 203–204, 205
Interdisciplinary Symposium, 15, 17
International Research Scientist Development Award (IRSDA), 299, 300–301
International Tobacco and Health Research and Capacity Building Program (TOBAC), 300, 302
intimate partner violence (IPV), 229, 259, 301
 alcohol and, 118
 in India, 301
 research symposium, 15
Intramural Program on Research on Women's Health (IPRWH), 31
irritable bowel syndrome (IBS), 202, 209–210, 289

J

Jackson Heart Study, 100, 103
joint replacement, total, 154

K

“Keep the Thread” Program, 31, 34
KEEPS (Kronos Early Estrogen Prevention Study), 96
 KEEPS-Cog, 106, 110
kidney diseases, 64, 202–221
Kronos Early Estrogen Prevention Study. *See* KEEPS

L

L. reuteri 6475, 309
laboratory animal medicine, 321–322
language associated with women's health research, 7
Latina women
 drug use, 232–233
 physical activity, 292
 See also Hispanic women
LGBTI (lesbian/gay/bisexual/transgender/intersex) research, 169–170, 262
Library of Integrated Network-Based Cellular Signatures (LINCS), 330

life-limiting conditions, 288–289
LIFE-Moms, 208, 213, 217–218
lifestyle interventions
 for cardiovascular disease, 205
 for diabetes, 203–204, 205
 for pregnant women (LIFE-Moms), 208, 213
LINCS, 330
Listeria monocytogenes, 132
Loan Repayment Program (NIMHD), 274–275
Look AHEAD trial, 205
low- and middle-income countries, 83, 129, 245, 264
low birthweight infants, 174, 291
lower urinary tract symptoms, prevention of, 12
lung cancer, 60, 70, 78
lung diseases, 93, 97–98
lupus (systemic lupus erythematosus), 137, 144, 150–151, 152–153
 malaria and, 131
 STOP Lupus, 155
 Twitter chat on, 156
 videos of patients, 153
lymphangi leiomyomatosis (LAM), 93, 97–98

M

macular degeneration, 91
magnetic resonance elastography, 160
magnetic resonance imaging. *See* MRI
major depressive disorder (MDD), 108
malaria, 75, 131
Malawi, 301, 302
mammalian target of rapamycin complex 1 (mTORC1), 97
MAPP, 12–13, 211, 215
maraviroc, 126
maternal infectious disease, 167–168
maternal oral health, 194
maternal undernutrition, 318
matrix metalloproteinase (MMP), 192
McKee, Sherry, 223

MeCP2 isoforms, 281

meetings, conferences, and workshops, 14–17

memory, 106

menarche, 181

menopausal hormone therapy, 109–110, 112–113, 262

- ELITE trial, 113
- window of opportunity for, 109–110

menopause, 106, 109–110, 289–290, 319

- antidepressant responses, 262
- cognition and, 261–262, 309
- complementary and botanical approaches, 308–309
- depression and, 262
- fat intake and stroke, 279
- fracture risk and, 289
- nonhormonal treatment for symptoms of (MsFLASH), 109, 112, 114
- predictors of cardiovascular disease in, 96
- SWAN study, 107–109, 112

menstrual cycle, HIV susceptibility and, 314

mental health, 119, 256–269

- aging and, 261–262
- global research and capacity building, 267
- NIH research budget for, 63
- pregnancy and postpartum period, 262–263
- severe mental illness, 267
- Women’s Mental Health Program, 257
- Women’s Mental Health Team, 257

mentoring, 19, 29–30, 34

metabolic conditions, 207, 213

metabolic syndrome, 111, 308

metabolism, 62, 312

metabolomics, 330

metformin, 203

methotrexate, 148

mHealth, 305

microbicides, 125–127, 139, 314

- Microbicides Trials Network (MTN), 125
- topical, 125–127

microbiome, 138, 206–207, 267, 293

migraines, 185, 199–200, 279–280, 280, 284

military

- Army STARRS study, 266
- health of women in, 179

mineralized tissue studies, 191–193

minorities, 269–276

- adolescent pregnancy, reducing, 271–272
- Committee on Women of Color in Biomedical Careers (WOC), 29–30
- criminal history/criminal justice system and, 270–271
- diversity in health-related research, 283
- enrollment data for clinical research, 41, 48–50, 53–54
- enrollment data for phase III clinical trials, 41, 50–54
- Healthy Aging in Neighborhoods of Diversity, 114
- inclusion as subjects in clinical research, 37–57
- Project SAFE (Sexual Awareness for Everyone), 270–271
- racial/ethnic categories (NIH), 37, 40
- sexual and gender minorities, health of, 169–170, 176
- stereotype threats, 253
- telemedicine and, 272
- Women of Color Health Data Book*, 30, 56
- Women of Color Research Network (WoCRn), 29, 34, 115
- See also* health disparities; inclusion of women and minorities; race/ethnicity

mission statement, vii, 1–2, 7

mitochondrial replacement therapy, 315

Mobile Health, 299, 301

Mobile Laboratory Coalition, 324

MOMDADDOCS, 246–247

MONEAD study, 280

monkeys, 311–312

MOON study, 148

morphine, 227–228

MRI (magnetic resonance imaging), 159–161

- fetal and newborn, 163

- robotic haptic feedback system and, 161
- steroid-based contrast agents, 163
- whole-breast, 159–160

MS. See multiple sclerosis

MsFLASH Network, 109, 112, 114

mucosal immunology, 136

mucus, 163

Multidimensional Treatment Foster Care (MTFC), 230

multiple sclerosis (MS), 137–138, 277, 278, 281

- CombiRx trial, 278
- DNA methylation and, 278
- estrogen and, 281

musculoskeletal diseases, 64, 144–158

myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), 199, 281

mycobacterial infections, 134–135

Mycoplasma genitalium, 134

myopia, 92

MyPregnancy Initiative, 168–169

N

nanoparticle delivery systems, 74, 159, 160, 161

National Cancer Institute (NCI), 20, 70–88

- accomplishments and activities, 72–80
- funding initiatives, workshops, and conferences, 80–85
- global initiatives, 81–85
- health disparities, 85–86
- STEM efforts, 80
- Web site, 71
- Women’s Health Officer, 71

National Center for Complementary and Integrative Health (NCCIH), 307–310

- botanical dietary supplements, 308
- dietary supplements, 307–308
- menopause, 308–309
- metabolic syndrome, 308
- NIH Strategic Plan, 309
- reproductive health, 308

National Eye Institute (NEI), 89–93

- accomplishments and highlights, 89–92
- corneal diseases, 89
- extraocular diseases, 89–90
- initiatives, 92–93
- lens, 90–91
- myopia, 92
- optic neuropathies, 91–92
- retinal diseases, 91

National Heart, Lung, and Blood Institute (NHLBI), 93–105

- abdominal aortic aneurysm, 95
- blood disorders, 98
- education/outreach activities, 99–100
- funding initiatives, workshops, and conferences, 102
- health disparities, 103–104
- The Heart Truth*, 99–100
- inclusion, 100
- lung diseases, 97–98
- menopausal predictors of cardiovascular disease, 96
- obesity, 95
- preeclampsia, 94
- sex- and age-dependent drug responses, 96–97
- sex-dependent differences in heart cells, 94–95
- sleep disorders, 98–99
- STEM efforts, 101–102
- Women’s Health Initiative (WHI), 100–101, 102
- Women’s Ischemia Syndrome Evaluation (WISE), 96

National Institute of Allergy and Infectious Diseases (NIAID), 20, 56, 122–143

- Centers for AIDS Research (CFAR), 130
- conferences and publications, 140
- health disparities, 140–141
- HIV/AIDS, 123–130
- immunology and immune-mediated diseases, 135–136
- inclusion activities, 122, 139

- infectious diseases other than HIV/AIDS, 130–135
- NIH Strategic Plan, 138–139
- research initiatives, 139–140
- STEM efforts, 139
- Trans-NIAID Women’s Health Research Work Group, 138–139
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 144–158
 - adolescent idiopathic scoliosis, 147
 - anterior cruciate ligament injuries, 147–148
 - autoimmune and rheumatic diseases, 154
 - bone biology, 146, 154
 - fibromyalgia, 151–152
 - funding initiatives, workshops, and conferences, 154–156
 - health disparities, 156
 - inclusion, 153
 - information dissemination, 153
 - lupus, 150–151, 152–153, 156
 - NIH Strategic Plan, 152
 - osteoarthritis (OA), 147–148, 154, 155
 - osteoporosis and fracture risk, 145–146
 - rheumatoid arthritis (RA), 144, 148–150, 152
 - scleroderma, 151
 - skin health, 152
- National Institute of Biomedical Imaging and Bioengineering (NIBIB), 158–166
 - breast cancer, 159–162
 - funding initiatives, workshops, and conferences, 165–166
 - health disparities, 166
 - inclusion, 165
 - NIH Strategic Plan, 165
 - other cancers, 162
 - reproductive health, 162–165
 - STEM efforts, 165
 - See *also* imaging technologies
- National Institute of Child Health and Human Development. See *Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)*
- National Institute of Dental and Craniofacial Research (NIDCR), 20, 187–201
 - autoimmune diseases and Sjögren’s syndrome, 187, 195–197
 - conferences and workshops, 200
 - craniofacial anomalies, 197–198
 - health disparities, 193–194, 200
 - HIV linked to oral health, 197
 - initiatives (FOAs), 199–200
 - maternal health and child oral health, 194
 - mineralized tissue studies, 191–193
 - NIH Strategic Plan, 198–199
 - oral HPV infection, 195
 - pain research, 188–189
 - periodontal health, 194
 - salivary hypofunction (dry mouth), 195
 - temporomandibular joint and muscle disorders, 187, 189–191
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 9, 32, 202–221
 - diabetes, 203–205, 218
 - digestive diseases, 209–210, 220
 - endocrinology, 208–209, 219
 - funding initiatives, workshops, and conferences, 215–217
 - health disparities, 217–218
 - Healthy Pregnancy Program, 207–208, 219
 - inclusion, 214
 - information and education initiatives, 214–215
 - NIH Strategic Plan, 213
 - obesity, 205–207, 218–219
 - program announcements, 216
 - Program Director for Women’s Urologic Health, 214
 - sex differences in metabolic and other conditions, 207, 213, 219
 - STEM efforts, 214
 - urologic health, 210–212, 213, 220
- National Institute of Environmental Health Sciences (NIEHS), 20, 240–251
 - accomplishments and activities, 240–244
 - BIRCWH awardee, 20

endocrine disruptors, 242, 244
 funding initiatives, workshops, and conferences, 247–249
 health disparities, 249
 household air pollution and cookstove research, 245, 249
 inclusion, 246
 National Toxicology Program, 242–243, 244–245
 prenatal exposures, 228–229, 242, 243–244
 Sister Study, 245
 STEM efforts, 246–247
 Women’s Health and Environment Across the Entire Lifespan, 246

National Institute of General Medical Sciences (NIGMS), 251–256
 accomplishments and activities, 252–255
 NIH Strategic Plan, 252–255

National Institute of Mental Health (NIMH), 20, 256–269
 accomplishments and activities, 257–268
 alliances and partnerships, 263–265
 clinical trials that analyzed data by sex, 266
 communication and social networking, 265
 educational outreach efforts, 265
 funding initiatives, workshops, and conferences, 266–267
 Global Grand Challenges, 264
 Global Research Hubs, 264
 health disparities, 257, 267–268
 inclusion efforts, 266
 ORDGMH and, 257, 263
 outreach to advocacy groups, 264–265
 risk factors, etiology, course of illness, and therapeutics, 260–263
 sex differences in brain and behavior, 257–260
 sex differences in neuroimaging, 260
 STEM efforts, 265–266
 Women’s Mental Health Program, 257
 Women’s Mental Health Team, 257

National Institute of Neurological Disorders and Stroke (NINDS), 20, 277–287
 chronic fatigue syndrome, 281
 chronic pain, 277–278, 279–280
 epilepsy, 277, 278, 280
 funded projects, 279–282, 285
 funding initiatives, workshops, and conferences, 283–284
 inclusion, 282–283
 mission, 277
 multiple sclerosis (MS), 277, 278, 281
 NIH Strategic Plan, 282
 research findings, 277–279
 Rett syndrome, 277, 278–279, 281
 STEM efforts, 283
 stroke, 277, 279, 280–281

National Institute of Nursing Research (NINR), 287–299
 accomplishments and activities, 288–292
 aging and menopause, 289–290
 chronic and life-limiting conditions, 288–289
 health disparities, 293, 294
 HIV/AIDS and sexual health, 294–295
 inclusion, 293
 initiatives, 293
 NIH Strategic Plan, 296–297
 obesity, physical activity, and disease prevention, 291–292
 pregnancy, childbirth, and perinatal health, 290–291
 STEM efforts, 295–296
 women’s health and, 288, 293–294

National Institute on Aging (NIA), 106–115
 Alzheimer’s disease, 106, 111
 behavioral and social research, 106, 111
 career development, 114
 cognitive health and decline, 106, 109–111
 communication and education initiatives, 114
 health disparities, 114
 menopausal hormone therapy, 109–110, 112–113
 menopausal transition, 109–110
 ovarian aging, 109, 113
 reproductive health and menopause, 106

- research initiatives, 112–113
- sex and gender analyses, 113–114
- SWAN study, 106, 107–109, 112
- WHIMS (Women’s Health Initiative Memory Study), 106, 112
- WHISCA (Women’s Health Initiative Study of Cognitive Aging), 106
- women’s aging and health, 107–109
- Women’s Health Liaison, 107
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), 116–122
 - cancer and alcohol use, 120
 - initiatives, workshops, and program announcements, 121–122
 - pregnancy, 118
 - prevention and treatment, 119–120
 - sex/gender differences, 116–118, 121
 - violence and alcohol use, 118
- National Institute on Deafness and Other Communication Disorders (NIDCD), 183–187
 - balance disorders, 185–186
 - cytomegalovirus, 184
 - otosclerosis, 184–185
 - voice disorders, 183–184
- National Institute on Drug Abuse (NIDA), 10, 20, 221–239
 - BIRCWH awardees, 20, 21
 - cannabis—sex differences, 225
 - clinical studies, sex differences and treatment strategies, 225–227
 - Clinical Trials Network (CTN), 235
 - health disparities, 232–233
 - interventions for women and girls in the criminal justice system, 230
 - leadership, 222
 - opioid use and receptors, 227–228
 - prenatal drug exposure, 228–229
 - preventing high-risk sexual behavior in youth, 229–230
 - publications, 236–237
 - SCOR program, 222–223
 - staff presentations, symposia, workshops, roundtables, and panels, 235–236
 - STEM efforts, 233–235
 - treatment medications for drug addictions, 230–232
 - Women and Sex/Gender Differences Research Program, 222
- National Institute on Minority Health and Health Disparities (NIMHD), 269–276
 - accomplishments and activities, 270–272
 - DREAM program, 274
 - funding initiatives, workshops, and conferences, 275–276
 - health disparities, 274, 276
 - inclusion, 274
 - Loan Repayment Program, 274–275
 - mission, 269
 - NIH Strategic Plan, 272–273
 - STEM efforts, 274–275
- National Institutes of Health. *See* NIH
- National Pain Strategy, 12
- National Primate Research Centers (NPRCs), 311–312
- National Toxicology Program, 242–243, 244–245
- National Women’s Health Week, 15–16
- Native Americans, 103, 194
 - AIDS and, 267
 - cancer and, 274
 - health disparities, 274
 - home-visiting intervention, 232
 - interventions for health promotion and disease prevention, 267
- Native Hawaiian/Pacific Islander women, 290
- NCI. *See* National Cancer Institute
- NEET proteins, 252
- NEI. *See* National Eye Institute
- NEIGHBOR consortium, 91–92
- neonatal ICU, 291
- neonatal MRI, 163
- neonates, 163, 177, 179
 - risk of HIV vaccination, 313

neuroimaging, 260
 neuroimmunology, 267
 neurologic research, 64, 300, 303
 neurology, BIRCWH research topics, 24
 neuropathic pain, 188
 neuropeptide systems, 258
 neurotechnology, BRAIN Initiative, 12, 283
 neutrophil cell death (NETosis), 150–151
 nevirapine (NVP), 72
 newborn brain injury, 174–175
 NHLBI. *See* National Heart, Lung, and Blood Institute
 NIAID. *See* National Institute of Allergy and Infectious Diseases
 NIAMS. *See* National Institute of Arthritis and Musculoskeletal and Skin Diseases
 NIBIB. *See* National Institute of Biomedical Imaging and Bioengineering
 NICHD. *See* Eunice Kennedy Shriver National Institute of Child Health and Human Development
 nicotine, 223–225, 231
 patch, 231
 NIDA. *See* National Institute on Drug Abuse
 NIDCR. *See* National Institute of Dental and Craniofacial Research
 NIDDK. *See* National Institute of Diabetes and Digestive and Kidney Diseases
 NIEHS. *See* National Institute of Environmental Health Sciences
 NIGMS. *See* National Institute of General Medical Sciences
 NIH
 Back-Up Child Care Program, 30
 budget for women’s health research, 59–67
 Common Fund, 328–330
 data reporting, changes in, 37
 Distinguished Women Scientists at NIH, 32
 funding life cycle, 40
 inclusion of women and minorities as subjects in clinical research, 4–5, 10, 37–57
 Intramural Program on Research on Women’s Health (IPRWH), 31
 “Keep the Thread” Program, 31, 34
 Office of Dietary Supplements, 20
 ORWH cofunded research, 8, 10, 12–14
 policy on inclusion of women and minorities as research subjects, 37
 research coding categories, 41
 scientific agenda for women’s health research, 2
 sex as a biological variable (SABV) in research studies, 4–5, 7, 10, 12, 14
 staff training in inclusion policy, 38
 Strategic Plan for Women’s Health Research, 2–5, 7, 34
 summary report of NIH inclusion data, 40–55
 Updates on Women in Science, 29
 Women in Science Web site, 29
 Working Group initiatives for NIH employees, 30–31
 Working Group on Women in Biomedical Careers, 28–31, 34
 Workshop on Enrollment and Retention of Participants in Clinical Trials, 55
 NIH Common Fund, 328–330
 genotype-tissue expression (GTEx), 329
 H3 Africa, 329
 High Risk, High Reward, 329–330
 Library of Integrated Network-Based Cellular Signatures (LINCS), 330
 metabolomics, 330
 NIH Institutes and Centers (ICs), 69–330
 See also specific Institutes and Centers by name
 NIH Reform Act (2006), 1, 60
 NIH Revitalization Act (1993), 1, 37
 NIMH. *See* National Institute of Mental Health
 NIMHD. *See* National Institute on Minority Health and Health Disparities
 NINDS. *See* National Institute of Neurological Disorders and Stroke
 nitric oxide synthetase (NOS), 73, 91, 94
 non-communicable diseases, 299, 301, 305
 Northwest Child Care Center, 31
 NOS. *See* nitric oxide synthetase
 Nurses’ Health Study (NHS), 260

O

- obesity, 103–104, 205–207, 216, 217, 291–292
 - breast cancer risk and, 75, 86
 - diabetes and, 312
 - fracture risk and, 289
 - genetic loci and, 241
 - genistein and, 309
 - heart disease and, 95
 - hot flashes and, 289
 - Look AHEAD trial, 205
 - physical activity and, 291–292
 - in pregnant women, 292, 293, 316–317
 - pregnancy, 293
 - prevention of, 272, 292
 - race/ethnicity and, 202, 291
 - references on, 218–219
 - stress and, 321
 - treatment, 205–206
 - weight gain in teen pregnancy and, 292
 - weight loss, race/ethnicity and, 103–104
 - weight-loss surgery, 205–206
 - weight management approach, 206
- OBSSR. *See* Office of Behavioral and Social Sciences Research
- obstetric pharmacology, 167, 177, 178, 263
- obstetrics, 24, 168
- Office for Research on Disparities and Global Mental Health (ORDGMH), 257, 263
- Office of Behavioral and Social Sciences Research (OBSSR), 10
- Office of Intramural Training and Education (OITE), 32
- Office of Research Infrastructure Programs (ORIP), 310–328
 - accomplishments and activities, 312–322
 - aging and menopause, 318–319
 - behavior, 319–321
 - career development, 321–322
 - diet, 319
 - disease, 312–314
 - funding initiatives, workshops, and conferences, 323–325
 - health disparities, 323
 - HIV/AIDS, 312–314
 - mission, 310
 - National Primate Research Centers (NPRCs), 311–312
 - NIH Strategic Plan, 311–312
 - reproductive health, 314–318
 - stem cells and regenerative medicine, 321
 - STEM efforts, 322
- Office of Research on Women’s Health. *See* ORWH
- Office of Strategic Coordination, 328–330
- OITE. *See* Office of Intramural Training and Education
- olaparib, 79
- omalizumab, 155
- OMB (Office of Management and Budget), 37
- oncology, BIRCWH research topics, 25
- ontogeny, 177
- opioid drugs, 227–228
 - central injection of, 189, 198–199
 - in pregnancy, 172, 227
- opioid receptors, 227–228, 232
- OPPERA study, 187, 189–190
- optic neuritis, 92
- optic neuropathies, 91–92
- oral contraceptives
 - for smoking cessation, 224
 - vulvodynia and, 174
- oral health, 64, 193–194, 197
- oral health disparities, 274, 293–294
- Oral HIV/AIDS Research Alliance (OHARA), 197
- orexin, 222
- organization of this report, ix
- ORIP. *See* Office of Research Infrastructure Programs
- orofacial pain, 187, 189–190, 199
- oropharyngeal cancer, 78
- ORWH (Office of Research on Women’s Health)

- activities related to NIH inclusion policy and reporting, 55–57
- budget (NIH), reporting of, 59
- career development activities, 19–35
- Clinical Research, Inclusion, and You (seminar), 55–56
- cooperation and partnership with NIH, 1–2, 7, 9, 34
- driving the NIH research agenda, 7–8
- mission/mission statement, vii, 1–2, 7, 19
- programs to advance women’s health research, 9–11
- research budget, use of, 7–8
- research meetings, conferences, and workshops, 14–17
- social networking activities, 14
- Web site, 14
- ORWH biomedical career development activities, 19–35
 - BIRCWH program, 19–25, 34
 - Committee on Women of Color in Biomedical Careers (WOC), 29–30
 - NIH Intramural Program on Research on Women’s Health (IPRWH), 31
 - NIH Women in Science Web site, 29
 - NIH Working Group on Women in Biomedical Careers, 28–31, 34
 - Reentry into Biomedical Research Careers program, 28, 34
 - Women of Color Research Network (WoCRn), 29, 34
 - Women’s Reproductive Health Research Career Development Program, 26–27
- ORWH research, 7–17
 - administrative supplemental funding, 10
 - Advancing Novel Science in Women’s Health Research Program (R21), 11
 - budget, use of, 7–8
 - cofunded research, 8, 10, 12–14
 - dissemination activities, 14–17
 - driving the NIH research agenda, 7–8
 - funding for meritorious research just missing IC pay line, 10–11
 - funding for research, 7, 19, 20, 26
 - funding opportunity announcements (FOAs), 7–8
 - historical perspective, 1–5
 - identifying topics of interest, 7
 - inclusion efforts, 8
 - NIH Strategic Plan and, 2–5, 7
 - R56 Program, 11
 - Research Enhancement Awards Program (REAP), 10–11
 - research mission, 7
 - SCOR on Sex Differences (P50), 9–10
 - shifting focus of, 7
 - targeted research topics, 7–8, 12–14
- osteoarthritis (OA), 147–148, 154
 - biomarkers for, 14
 - inflammation and, 155
 - post-traumatic, 147–148
 - sex/gender differences in, 175
- Osteoarthritis Initiative (OAI), 14
- osteocalcin, 146
- osteonecrosis of the jaw (ONJ), 191, 192–193, 199
- osteoporosis, 130, 144, 145–146, 191–192, 308–309
 - periodontal disease and, 194
 - premenopausal, 145
 - probiotics and, 309
- Osteoporosis and Related Bone Diseases National Resource Center, 144
- osteoporotic fractures, 144
- otosclerosis, 184–185
- ovarian aging, 109
- ovarian cancer, 70, 71, 79–80, 113, 162
 - treatment, 253
- ovaries
 - gamete and embryo quality, 179
 - primary ovarian insufficiency, 173, 179, 207
 - removal of, 80
- oxytocin, 222, 258–259

P

- P2X4 receptors, 117
- PAHs, 242
- pain, 188–189, 283–284
 - annual NIH symposium on, 16
 - central injection of opioids, 189, 198–199
 - chronic, 12, 16, 151–152, 252–253, 277–278, 279–280
 - chronic overlapping pain conditions, 188, 199, 284
 - chronic pelvic pain, 12–13, 211, 215
 - during pregnancy, 172
 - education, 12
 - estradiol and, 189
 - fibromyalgia, 151–152
 - following childbirth, 252–253
 - gallbladder, 210
 - health disparities, 156
 - management and pain drugs, 12, 189, 198–199
 - National Pain Strategy, 12
 - neuropathic, 188
 - NIH Pain Consortium, 12, 16, 200, 284
 - orofacial, 187, 189–190
 - perception, racial disparities in, 284–285
 - research at NIH, 12
 - in rheumatoid arthritis, 149
 - sex differences in peripheral pain receptors, 278
 - Trans-NIH Sleep/Pain Workshop, 16
- PALB2 gene, 70, 72
- Pap smear, 76
- PARP1 inhibitor therapy, 209
- patient-oriented research, 40
- PBDE levels, 241
- PCOS. *See* polycystic ovary syndrome
- pediatric infectious disease, 167–168
- pediatric pharmacology, 168, 177, 178
- pediatrics, BIRCWH research topics, 25
- peer review, 38
- pelvic organ prolapse (POP), 171
- pelvic pain, chronic, 12–13, 211, 215
- perinatal period, 168, 290–291, 317–318
- periodontal health, 194
- peripheral nerve injury, hypersensitivity and, 252–253
- personalized medicine, 324
- pesticides, 244
- pharmacology
 - developmental, role of ontogeny, 177
 - obstetric and pediatric, 168, 177, 178
- phase III clinical trials
 - enrollment data for minorities in, 41, 50–54
 - enrollment data for women in, 41, 45, 46–47, 53–54
 - inclusion of women and minorities in, 37, 38, 39
- phthalates, 244
- physical activity, 72, 108, 291–292
- placenta, 168, 177, 180, 216–217
- Plasmodium falciparum*, 75, 131
- PLUS Consortium, 215
- PMI 5011, 308
- pneumonia, 164
- POI. *See* primary ovarian insufficiency
- point-of-care (POC)
 - tests for STDs, 162
 - ultrasound for maternal health, 163–164
- polidocanol foam (PF), 315
- polycystic ovary syndrome (PCOS), 170, 316
- postpartum depression, 172, 258, 263, 291
- postpartum mental health, 262–263
- postpartum problems, 291
- posttraumatic stress disorder. *See* PTSD
- precision disease modeling, 323
- Precision Medicine Initiative, 221–222
- preclinical research, inclusion of both sexes in, iv, 7, 10
- preeclampsia, 94, 171, 180, 181, 273, 290
- prefrontal cortex, 259, 260
- pregnancy, 168, 171–172, 290–291, 316–318
 - alcohol use and, 118, 121, 315

antibiotic use and, 171–172, 317
 antidepressant use and, 263
 antiepileptic drug clearance and seizure in, 278
 cesarean delivery for first-time mothers, 172
 chemotherapy during, 242–243
 chorioamnionitis, 317
 diet and weight change during, 178
 drug use in, 227–229
 environmental factors and, 242
 gestational diabetes, 178, 202, 204–205, 208, 271
 HAPO study, 208
 Healthy Pregnancy Program, 207–208, 219
 Human Placenta Project, 168, 180
 hypertension during, long-term effects, 110
 inclusion of pregnant women in clinical research, 56–57
 inflammation and pregnancy outcomes, 272
 influenza during, 172
 influenza vaccination and, 133, 240
 LIFE-Moms, 208, 213, 217–218
 lifestyle interventions, 208
 malaria associated with, 131
 maternal and child health, 169
 maternal undernutrition, 318
 maternity leave benefits, 111
 mental health during, 262–263
 MyPregnancy Initiative, 168–169
 obesity/weight and, 292, 293, 316–317
 “omics” approach to health and outcomes, 177
 opioids and, 172, 227
 PBDE levels and, 241
 placenta, 168, 177, 180, 216–217
 pregnancy-related diseases, targets and treatments, 177
 prenatal drug exposures, 228–229, 317, 318
 preterm births, 173, 263, 273, 317
 Program in Perinatal Research and Obstetrics (PPRO), 168
 PTSD and, 263, 290
 schistosomiasis and, 131–132
 smoking and, 228, 242
 teen/adolescent, 170, 271–272
 The 37 Percent (meeting), 179
 unwanted, 179, 180
 uterine vascular remodeling, 317
 vaccines during, 57, 133, 240
 variations in length of, 241
 vessel clots following, 282
 prenatal exposures, 228–229, 242, 243–244, 317, 318
 androgen exposure, 316
 prenatal health, 317–318
 President’s Emergency Plan for AIDS Relief (PEPFAR), 300, 303
 preterm births, 173, 263, 273, 317
 preventing mother-to-child transmission of HIV (PMTCT), 300, 303–304, 306
 primary open angle glaucoma (POAG), 91
 primary ovarian insufficiency (POI), 173, 179, 207
 primate research, 311–312
 probiotics, 309
 progesterone, 136–137
 vaginal, 173
 Project SAFE (Sexual Awareness for Everyone), 270–271
 computer-delivered version (C-SAFE), 270–271
 in Spanish (C-SEGURA), 270–271
 prolactin, 188
 prolapse. *See* pelvic organ prolapse
 PROMISE Study, 127–128, 130
 prostaglandin E2 (PGE2), 315
 proton-electron double-resonance imaging, 161
 psychology, BIRCWH research topics, 25
 psychotic depression, 266
 PTSD (posttraumatic stress disorder), 223–224, 260, 291
 during pregnancy, 263, 290
 puberty, 260, 261
 pulmonary diseases, 25, 61

Q

Québec, Fonds de Recherche du (FRQ), 31

R

R56 Program, 11

RA. *See* rheumatoid arthritis

race/ethnicity

aggregate enrollment in research studies, 48–54

asthma risk and, 104

diabetes and heart disease risk, 204

disparities in pain perception, 284–285

enrollment in clinical research, 48–50, 53–54

enrollment in phase III clinical trials, 50–54

Health of Women of Color (symposium), 17

obesity and, 202, 291

post-stroke cognitive decline in Mexican-Americans, 285

racial and ethnic categories, 40

sleep disturbance and, 108–109

standards for data classification and reporting, 37

stereotype threats, 253

substance abuse treatment and, 232

See also health disparities; inclusion of women and minorities; minorities

REAP (Research Enhancement Awards Program), 10–11

Reasons for Geographic and Racial Differences in Stroke (REGARDS), 285

Red Dress symbol, 99

Reentry into Biomedical Research Careers program, 28, 34

REGARDS (Reasons for Geographic and Racial Differences in Stroke), 285

regenerative medicine, 321

reproductive health, 106, 162–165, 167, 308, 314–318

environmental and genetic factors, 254

fertility and contraception, 314–316

NIH research budget for, 61

Reproductive Scientist Development Program, 176

research

careers in. *See* career development

dissemination activities, 14–17

ORWH, 7–17

on women's health. *See* women's health research

See also specific NIH Institutes and Centers

Research Enhancement Awards Program (REAP), 10–11

retinal diseases, 91

Rett syndrome, 277, 278–279, 281

rheumatic diseases in children and adults, 155

rheumatoid arthritis (RA), 144, 148–150, 152

age and prescribing, 148–149

genetic variants, 149–150

methotrexate, 148

sleep and, 149

rheumatology, BIRCWH research topics, 25

RNA splicing regulation, 255

RNase 7, 212

robotic haptic feedback system, 161

Roux-en-Y gastric bypass (RYGB), 206

rural women, 292

S

SABV. *See* sex as a biological variable

salivary hypofunction (dry mouth), 195

SAS1B, 316

schistosomiasis, 131–132

Science Education Partnership Awards (SEPA), 310, 322, 323, 324

Science of Sex and Gender in Human Health (online courses), 33, 34

science, technology, engineering, and mathematics. *See* STEM

scleroderma, 138, 151

SCOR (Specialized Centers of Research) on Sex Differences, 8, 9–10, 222–223

seizures. *See* epilepsy

self-harm, 261

SEPA (Science Education Partnership Awards), 310, 322, 323, 324

sepsis, 293

sertraline, 263

sex

- clinical trials that analyzed data by sex (NIMH), 266
- enrollment data for clinical research, 43–45, 53–54
- enrollment data for phase III clinical trials, 45–47, 53–54
- inclusion of both sexes in research projects, 4–5, 10, 37–57
- NIH research budget by, 67
- Studying Sex to Strengthen Science (Web site), 14

sex and gender factors, 174–176

- A to Z Guide: Sex and Gender Influences on Health, 14
- antagonistic co-evolution of males and females, 254
- drug use and antisocial behavior, 9
- in emergency care, 284
- Health of Women of Color (symposium), 17
- “Influence of Sex and Gender on Disease Expression and Treatment,” 33
- online courses: Science of Sex and Gender in Human Health, 33, 34
- reporting of sex/gender categories, 40
- Science of Sex and Gender in Human Health, 33, 34
- SCORs (Specialized Centers of Research), 9–10

sex as a biological variable (SABV), 4–5, 7, 10

- in BRAIN Initiative, 12
- online information about, 14
- in pain research, 12

sex development, disorders of (DSD), 169, 179

sex/gender differences, 222, 293, 311

- administrative supplements for research on, 8, 9–10, 106, 121, 140, 213, 216, 247, 255, 293
- affecting women’s health, 9–11
- aging and, 113–114
- alcohol and, 116–118, 121
- antibiotic exposure in early life and, 206–207
- in asthma, 97, 104
- in brain and behavior, 257–260
- in cannabis use/effects, 225
- in CVD risk, 207
- in cystic fibrosis, 98
- developmental origins of, 174–175
- in diabetes, 13
- in disinhibition, 226–227
- in drug responses, 96–97
- in drug use/abuse, 9, 223–228
- in dura mater and migraine, 279–280
- fragile X and, 207
- in free fatty acid flux, 175
- in heart cells, 94–95
- in hypertension, 175–176
- in IBS treatment, 209
- in kidney/urologic diseases, 9
- meetings and workshops on, 15–17
- in metabolic conditions, 207, 213
- in neuroimaging, 260
- in neuropeptide systems, 258
- in noradrenergic sensitivity, 9
- online guide to, 14
- ORWH programs on, 9–11
- in osteoarthritis, 175
- in peripheral pain receptors, 278
- in quality of life after stroke, 279
- in response to opioid drugs, 198–199
- SCOR program on, 8, 9–10, 106, 222–223
- in smoking and nicotine, 9–10, 223–225
- treatment strategies and, 225–227

sex hormones, 132–133, 189, 207

- behavioral effects of, 320

sexual abuse, childhood, long-term effects of, 108

sexual and gender minority populations (formerly LGBTI), 169–170, 176, 262

sexually transmitted diseases (STDs), 162–163, 259, 295

- Center for Point-of-Care Tests for, 162

cervical mucus, 163
 hormone influences on vaginal epithelium, 318
 interventions for Hispanic women, 270–271
 point-of-care (POC) tests for, 162
 prevention of transmission, 318
 Project SAFE (Sexual Awareness for Everyone), 270–271
 Sfswap, 255
 sickle cell disease (SCD), 98
 SIDS, 178
 sildenafil, 96–97
 sirolimus, 98
 Sister Study, 245
 Sjögren's syndrome (SS), 187, 195–197
 genetics, 197
 International Collaborative Clinical Alliance (SICCA), 187, 195–196
 Registry, 90
 skin cancer, 152
 skin diseases, 144–158, 312
 skin health, 152
 SLE (systemic lupus erythematosus). *See* lupus
 sleep, nighttime breastfeeding and, 290
 sleep apnea, 98–99
 sleep disorders, 98–99
 chronic pain and, 16
 RA pain and, 149
 SWAN Sleep Study, 108–109, 112
 Sleep/Pain Workshop, 16
 small blood vessels, 16–17
 smoking, 223–225
 breast cancer risk, 75
 cessation, 223, 224–225
 during pregnancy, 228, 242
 prenatal exposure, 228
 reduced nicotine content cigarettes, 231
 social networking, 14, 265
 spasmodic dysphonia (SD), 183–184
 Specialized Centers of Research. *See* SCOR
 The Spelman Project, 179
 Sperm Acrosomal SLLP1 Binding (SAS1B), 316
 sphincter of Oddi dysfunction (SOD), 210
 sponge compound, 254–255
 STDs. *See* sexually transmitted diseases
 stem cells, 321
 STEM (science, technology, engineering, and mathematics) efforts
 Fogarty International Center, 305
 National Cancer Institute, 80
 National Heart, Lung, and Blood Institute, 101–102
 National Institute of Allergy and Infectious Diseases, 139
 National Institute of Biomedical Imaging and Bioengineering, 165
 National Institute of Diabetes and Digestive and Kidney Diseases, 214
 National Institute of Environmental Health Sciences, 246–247
 National Institute of Mental Health, 265–266
 National Institute of Neurological Disorders and Stroke, 283
 National Institute of Nursing Research, 295–296
 National Institute on Drug Abuse, 233–235
 National Institute on Minority Health and Health Disparities, 274–275
 Office of Research Infrastructure Programs, 322
 STEM games, 323–324
 stereotype threats, 253
 stillbirths, 164, 178
 STOP Lupus, 155
 STOP-PD, 266
 Strategic Plan for Women's Health Research (NIH), 2–5, 7
 ORWH support of, 34
 shifting focus for, 7
 See also specific Institutes and Centers
 stress, 247, 258, 259, 293, 319–321
 in adolescence, 320–321
 chronic, 319–320
 hormones and, 320
 obesity and, 321

stroke, 95, 100, 101, 103, 277, 279, 280–281
 emergency care for, 284
 fat intake and, 279
 fetal cells, role in recovery, 280
 literacy and intent to call 9-1-1, 285
 post-stroke cognitive decline, 285
 quality of life (QOL) after, 279
 Reasons for Geographic and Racial Differences
 in (REGARDS), 285
 risk factors, 95, 280–281
Studying Sex to Strengthen Science (Web site), 14
substance abuse
 NIH research budget for, 62
 prevention and treatment, 119
sudden infant death syndrome (SIDS), 178
suicide, 230
SWAN (Study of Women’s Health Across the
 Nation), 106, 107–109, 112
SWAN Sleep Study, 108–109, 112
systemic lupus erythematosus (SLE). *See* lupus
systemic sclerosis, 138

T

T cells, regulatory (Tregs), 136–137
tamoxifen, cognition and, 110–111
targeted research topics, 7–8, 12–14
TCDD, 318
teens. *See* adolescents
teeth, 191–193
telemedicine, 272
temporomandibular joint, 166, 199, 200
 imaging of, 190–191
 reconstruction of, 191
temporomandibular joint disorder (TMD), 187,
 189–191, 199
 diagnostic criteria for, 190
 genetic factors and, 16
 sex hormones and, 189, 198
tenofovir, 129–130
tenure track investigators program, 246

testosterone, influenza vaccination and, 132–133
TETRAD, 155
TGF β inducible early gene (TIEG), 192
thermally targeted drug delivery, 160
thyroid eye disease, 90
thyroid hormone, 146
TOBAC program, 300, 302
tobacco
 cessation, budget for, 62
 gender-sensitive treatment, 9–10
 See also smoking
TODAY study, 204, 215
tomography
 combined with MRI, 159
 digital breast tomosynthesis (DBT), 159
topical microbicides, 125–127
toxicology, 65
Trans-NIAID Women’s Health Research Work
 Group, 138–139
transwomen of color, 272
trauma, childhood
 long-term effects of, 108
 metabolic syndrome and, 111
trauma research training, 299, 300, 306
trimethoprim and sulfamethoxazole (TMP/SMZ), 212
Trypanosoma cruzi, 132
tuberculosis (TB), 134, 177
Turner syndrome, 16

U

ultrasound, 160–161, 163–164
unemployment, after chemotherapy, 74
urinary incontinence, 12, 289–290
urinary tract infections (UTIs), 9, 12, 210–212
urologic diseases/health, 12–13, 64, 210–212, 213,
 220
uropathogenic *Escherichia coli* (UPEC), 211
uterine biomagnetic signals, 164
uterine fibroids, 173, 180, 240, 250

uterine vascular remodeling, 317
uterus
 endocrine disruption of, 321
 estrogen-related responses in, 242
UTIs. *See* urinary tract infections

V

vaccines
 BCG, 313
 development of, 136, 273
 during pregnancy, 57
 HIV, 128, 273, 313
 HPV, 70, 77, 78, 82
 influenza, 132–133
 OPV (Oral Polio Vaccine), 313
vaginal epithelium, hormone influences on, 318
vaginal immune response, 136
vaginal transmission of HIV, 313, 314
varenicline, 231
Varmus, Harold, 222
vascular cognitive impairment, 303
vasopressin, 258
vesicoureteral reflux (VUR), 212
vestibular research, 185–186
veterinarians, 321–322
violence against women. *See* intimate partner violence
vitamin D, 130, 147, 171
voice disorders, 183–184, 186
VOICE trials, 125–126
vulvodynia, 173–174, 178–179

W

Web site (ORWH), 14
weight, 206
 Weight-Control Information Network, 214
 weight loss surgery, 205–206, 215–216, 217
 See also obesity

West Virginia Health Sciences Technology Academy, 322

WHI. *See* Women's Health Initiative

WIHS. *See* Women's Interagency HIV Study

WOC. *See* Committee on Women of Color in Biomedical Careers

women

 adding to studies already in progress, 5
 biomedical career development, 19–35
 enrollment data for clinical research, 4, 41, 44–45, 53–54
 enrollment data for phase III clinical trials, 41, 45, 46–47, 53–54
 inclusion as subjects in clinical research, 4–5, 7, 10, 37–57
 life expectancy, 107
 older women, 106–115
 See also inclusion of women and minorities

Women in Science Web site, 29

Women of Color Health Data Book, 30, 56

Women of Color Research Network (WoCRn), 29, 34, 113

Women's Cancer Summits, 84

women's health, 170–174

 across the lifespan, 246, 299, 300, 303

 international, 171

 National Institute of Nursing Research, 288, 293–294

Women's Health Congress, 15

Women's Health Initiative (WHI), 100–101, 102, 106

 Memory Study (WHIMS), 106, 112

 Observational Study (WHI-OS), 194

 Study of Cognitive Aging (WHISCA), 106, 112–113

Women's Health: NIH Has Increased Its Efforts to Include Women in Research (report), 37

women's health research (WHR)

 Advancing Novel Science in Women's Health Research Program (R21), 11

 career development support by ORWH (summary), 34

 language associated with, 7

NIH budget for, 59–67
NIH Intramural Program on Research on Women's Health (IPRWH), 31
ORWH research, 7–17
Report of NIH Institutes and Centers, 69–330
See also career development; ORWH (Office of Research on Women's Health)
Women's Health Week, National, 15–16
Women's Interagency HIV Study (WIHS), 123, 124, 139
Women's Ischemia Syndrome Evaluation (WISE), 96
Women's Mental Health Program, 257
Women's Mental Health Team, 257
Women's Reproductive Health Research (WRHR) Career Development Program, 26–27, 34, 176
Working Group on Women in Biomedical Careers, 28–31, 34
workplace culture, impact of, 283
workshops, 14–17
WRHR. *See* Women's Reproductive Health Research Career Development Program

Z

zebrafish, 254, 318, 324
Zimbabwe, orphan girls in, 171